What is Leerink Partnrs’ Estimate for SPRY FY2027 Earnings?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Leerink Partnrs lowered their FY2027 earnings per share estimates for shares of ARS Pharmaceuticals in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings per share of $0.55 for the year, down from their previous estimate of $0.60. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.64) per share.

Other equities analysts have also recently issued reports about the company. Leerink Partners increased their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $24.00.

ARS Pharmaceuticals Price Performance

Shares of ARS Pharmaceuticals stock opened at $14.01 on Friday. The stock’s 50-day moving average is $14.63 and its 200 day moving average is $11.73. ARS Pharmaceuticals has a one year low of $4.28 and a one year high of $18.51. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -27.47 and a beta of 0.90.

Insider Activity at ARS Pharmaceuticals

In related news, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $18.04, for a total value of $9,533,346.24. Following the transaction, the insider now owns 5,274,735 shares in the company, valued at $95,156,219.40. This trade represents a 9.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sarina Tanimoto sold 100,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $14.88, for a total transaction of $1,488,000.00. Following the sale, the insider now owns 1,298,499 shares of the company’s stock, valued at approximately $19,321,665.12. This represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,584,351 shares of company stock worth $24,152,378. 40.10% of the stock is owned by company insiders.

Institutional Trading of ARS Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. increased its position in ARS Pharmaceuticals by 14.8% during the first quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock valued at $110,999,000 after acquiring an additional 1,401,299 shares during the last quarter. Vanguard Group Inc. boosted its stake in ARS Pharmaceuticals by 37.0% during the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after buying an additional 779,969 shares during the last quarter. State Street Corp lifted its position in ARS Pharmaceuticals by 10.4% during the third quarter. State Street Corp now owns 2,049,542 shares of the company’s stock valued at $29,718,000 after purchasing an additional 193,321 shares during the last quarter. Geode Capital Management LLC increased its stake in ARS Pharmaceuticals by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company’s stock worth $17,909,000 after acquiring an additional 38,927 shares during the last quarter. Finally, Royce & Associates LP boosted its stake in shares of ARS Pharmaceuticals by 7.1% during the 3rd quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock worth $10,026,000 after purchasing an additional 45,755 shares during the period. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.